^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype

Excerpt:
In both GNAQ and BRAF cells, the AZD8055/selumetinib combination at different dose combinations consistently reduced cell viability by more than 50% (“fractional activity” (Fa) >0.5) in a synergistic manner (combination index (CI) values <1) (Figure 1A). 
DOI:
10.1371/journal.pone.0040439